Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)
China
· Delayed Price · Currency is CNY 30.50
+1.96 (6.87%)
At close: Mar 9, 2026
SHA:688319 Revenue
In the year 2025, Chengdu Olymvax Biopharmaceuticals had annual revenue of 704.16M CNY with 19.58% growth. Chengdu Olymvax Biopharmaceuticals had revenue of 197.24M in the quarter ending December 31, 2025, a decrease of -2.46%.
Revenue
704.16M
Revenue Growth
+19.58%
P/S Ratio
17.57
Revenue / Employee
1.50M
Employees
463
Market Cap
12.37B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 704.16M | 115.30M | 19.58% |
| Dec 31, 2024 | 588.86M | 92.74M | 18.69% |
| Dec 31, 2023 | 496.12M | -51.36M | -9.38% |
| Dec 31, 2022 | 547.48M | 60.33M | 12.38% |
| Dec 31, 2021 | 487.15M | 167.04M | 52.18% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Hualan Biological Vaccine | 976.44M |
| Beijing Hotgen Biotech | 407.69M |
| Staidson (Beijing) BioPharmaceuticals | 244.37M |
| Chengzhi | 11.53B |
| InventisBio | 37.33M |
| HitGen | 525.57M |
| China Resources Boya Bio-pharmaceutical Group Co.,Ltd | 1.96B |
| Vcanbio Cell & Gene Engineering Corp., | 1.47B |